Project profile — Support to COVID-19 Diagnostics

• Africa, regional (20.00%)
• America, regional (20.00%)
• Asia, regional (20.00%)
• Oceania, regional (20.00%)
• Europe, regional (20.00%)

• Basic Health: Infectious disease control (12250) (50.00%)
• Health: COVID-19 control (12264) (50.00%)

• Gender equality (significant objective)
• Environmental sustainability (cross-cutting) (not targeted)
• Participatory development and good governance (not targeted)
• Trade development (not targeted)
• Biodiversity (not targeted)
• Climate change mitigation (not targeted)
• Climate Change Adaptation (not targeted)
• Urban issues (not targeted)
• Desertification (not targeted)
• Children's issues (not targeted)
• Youth Issues (not targeted)
• Disaster Risk Reduction(DRR) (not targeted)
• Indigenous Issues (not targeted)
• Disability (not targeted)
• Nutrition (not targeted)
• ICT as a tool for development (not targeted)

This project supports the Foundation for Innovative New Diagnostics (FIND) in accelerating the roll-out of safe, affordable, and effective COVID-19 diagnostics in Low- and Lower-Middle Income Countries. It contributes to the global COVID-19 response set out in the Access to COVID-19 Tools Accelerator Diagnostics Partnership. Project activities include: (1) developing rapid and affordable COVID-19 tests for use in lower-income countries; and (2) building and deploying new testing and market shaping strategies to meet the changing needs of the pandemic response.

The expected outcomes of this project include: (1) increased capacity of manufacturers to research and develop rapid diagnostic tests; and (2) enhanced access to simple, accurate, and affordable COVID-19 tests for Lower-Middle Income Countries.

Results achieved as of May 2023 include: (1) procured 193 million tests through the Access to COVID-19 Tools Accelerator Diagnostics Consortium for Lower-Middle Income Countries; and (2) reduced COVID-19 test pricing. This includes reducing the polymerase chain reaction test price from US$20-30, to less than $10 per test, and quality-assured rapid diagnostic tests from more than US$5 to less than US$1.

• Proactive disclosure
• Related activities:
• Support to COVID-19 diagnostics
• Support to COVID-19 Diagnostics